Adaptive Biotechnologies forecasted at least 20% MRD revenue growth for 2026, driven by ClonoSeq uptake, EMR integrations, and broader clinical endorsement of minimal residual disease as a validated endpoint. The company reported strong Q4 and full‑year 2025 results and guided to higher test volumes and pricing tailwinds tied to payor renegotiations. A Labcorp clinician survey highlighted MRD and multi‑cancer early detection (MCED) as the most promising cancer diagnostic technologies, reinforcing commercial and clinical momentum. For diagnostic platform companies and trial sponsors, the combination of rising test adoption and regulatory recognition suggests expanding demand for blood‑based monitoring in oncology trials and post‑treatment surveillance.